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LE RS TO E EDH 
I read with interest the study of Sclfers et al. (I) on the in vitro and 
in viva inotropic effects of the beta,-agonist terbutaline. After the 
definition by our group of the role of beta,-adrenoceptw stimulation in 
the activation of adenylate cycla% and production of positive inOtrOpiC 
etfcas in vitro, we, too, have u.sed synthetic beta,-agonists, in our WC 
MlhutamoI, to explore the in vivo cffccts of beta?-adrenweptor 
stimulation (2.3). In keeping with our earlier sunlies (4). Sclfers et al 
found that b&+-agonists product? positive inotropic &feSts it1 Vitro. 
Tkcy &o ww ;~hlr: to d~~~(~~str~~t~ for the lirst time in humans a 
pushive inotropic elfcct in viva. 
of perhaps more interest is the sensitization of cardiac beta:* 
adrentxeptors induced hy b4%ii,-ill~t~lgO99iSt IICi~ttWflt~ fibt &tCCtCd in 
vitro itnd subsequently dcmonstruted in vivo (45). This linding of a 
,~~~tornll~~ et al. (0) and shown to occur despite no alteration in beta,- 
adrenoc~ptor density. In their discussio,l, Schtifers et al. compare their 
current study showing ne alteration of responsiveness to terhutaline 
.tfter 3 weeks of beta,-adrcnergic blocking agent treatment with our 
study showing increased responsiveness to intracoronary salhutamol in 
patients previously treated with beta,-blockers (L5). They speculate on 
F&Ac rea.sons why they failed to detect beta?-adrcnoceptor sensiti- 
zation during 3 weeks of treatment with hisoprolul. Some of ths 
questions raised c;ln be answered hy refcrcncc to our published study 
of the responses of normal volunteers to intravenous salbutamol after 
hisoprolol treatment (7). We fuund that in normal volunteers !. wcclks 
of treatment with hisoprolol increased cardiac responsiveness to 
bet~+tdrcnoceptur stimulation. Conscqusntly, the failure of Schiifers 
ct al, to detect beta,-adrenoccptur sensitization in viva cannot IX 
altribulcd to the use of inrravcnous infusions rather than intracoronrry 
injections nor to the use of normal volunteers rather than patients. We 
studied the responsrs to sulbutamol4ll h after withdrawal of laisoprolol 
rather than during continuing treiatmcnt be~ut.se this allowed us to 
simult~neou~~ assess ~tn,*~d~no~pto~-medinted effects. Howevur. 
continainep bisuprolol treatment (as used by Schifers et al.) should not 
have si@i~antly reducsd the responses to tcrbutalinc bccausc calcu- 
lated beta2-adrenoceptor occupnucy should be 6% (8). 
The diEerenee between the two studies is of therapeutic impor- 
tam: ki!W.usC, in S&fers et al. Spc~datc, beta,qgmists CiW be used 
in patients with heart failure to provide inotropic support. Our in vitro 
aM1 in viw findings would sugest that hisoprolol treatment will 
actually lead to enhanced beta,-adrenoceptor-mediated cardiiic re- 
SpORWS. Consequently, it is possible that an enhanced positive ino- 
tropir‘ cAk3 of the endogenous ratecholamines adrenaline and nora- 
drmline. acting through beta+rdrenoceptors, accounts for the 
bnehehl clinical effects of long-term beta,-blocker therapy seeu in 
patients with heart failure (9). Further studies are needed to examine 
this hypothesis. 
&?pg 
WC very much ~l~pre~~~~l~ the inreres1 of all in our rcccnt study on the 
in vitro md is vivo effects of t~rb~~talin~ in the human Ivan ( I ). An 
lrrescnt we do no1 know why we did not find any beta,-adrenergic 
receptor seositizrtion in the h&thy volunteers afIcr the ~-WC& 
trCiitIjIont with the het;r,-adrenergic receptor-selective antagonist 
bisoprolol (IO mg). whereas Hall et al. (2,3) did tind such sensitization 
in pikItS with coronary artery discasc ilftCr long-term treatment with 
the beta,-adrent@ rcccptor-sclectivvs antagonist iitenolol(2) and in 
healthy volunteers uftcr long-term treatment with the beta,-adrenergic 
receptor-selective antagonist bis~lpr~~!ol (3). In our study (I) WC 
speculated that the dilferencc ~wuld be due to the injection of 
salbutamnl in tbc right coronary artery of patients in the Hall et al. (2) 
study. whsrens terh~talin~ was infused intravenously in volunteers in 
our study, hut this does nut !tppear to he the reason bccausc Hall et al. 
also infused intravenous salbutamol in healthy volunteers and obtained 
an increased heart rate response to salbutamol after bisoprolol treat- 
ment (3). Thus, the main difference between the two studies in 
volunteers (1.3) is &at we examined the effects of terhutaline during 
continuous bisoprolol treatment, whereas Hall et al. examined the 
effects of salbutamol48 h after withdrawal of bisoprolol. However, the 
sensitizing effect of bisoprolol on salbutamol infusion-induced tachy- 
cardia in the volunteers was much weaker than on intracoronary 
salbutamol-induced tachgcardia in the patients with coronary artery 
disease. In the volunteers the dose at which salbutamol increased heart 
rate by 40 beats/mitt was 2.9 rcgkg before and I.9 pg./kg after 
hisoprolol treatment (rntio 1.5). and dilferences were obvious only at 
the hvo highest doses of salbutamol (3), whereas after intracoronary 
injections in the patients. the dose at which salbutamol increased heart 
rate by 30 beatslmin was 8.91 pg before and 2.29 erg after atenolol 
(ratic 3.9), and at each dose salb~tamol was more elfective in the 
atenolol-treated patients than in the nontreated patients (2). We 
believe that this is at least partly in line with our view that the major 
difference between our data and those of Hall et al. is the comparison 
of volunteers with patients and intravenous infusion with intracoronary 
We nute with intcrcst the study by Miiggc et al. (1). which appcitred in 
the same issue ot’ the Sournal as our own study (7). which examined left 
atria1 appendage function and thrc~nboembolism in patients with atrial 
fibrillation. Although there were many points of agreement between 
the studies. particularly with regard to Ihe relation between luw left 
atrial appendage blood vclucity and the risk of spontaneous echo 
contrast and thromhus furmation, somewhat diRering conclusions wcrc 
reached with regard tu the relaliun between IOW left atrial appcndagc 
blood vclucity and previous emholic cvcnts. Miigge et al. found that h 
(60%) of IO patients wi h nonvalvular atrial fibrillation imd a “low Iluw 
prolilc” (~25 cm/s) left atrial appcndagc Doppler bluud Ilow pttertl 
had tl history of systemic cmhulic events (ischemic stroke or peripheral 
cmbulismj. whereas only I (5%) of 19 patients with a “high Row 
profile” (>25 cm/s) velocity pattern had a bistoq of such events (p < 
0.05). It was concluded from these results that patients with low left 
atrial appendage blood velocity may be at increased risk fur thrumbu- 
embulic complications. However, it is nntablc that the mean left atrial 
appendage blood velocity in the additional group of 12 patients with 
chronic atrial fibrillation and mitral stenosis studied by Miigge et al. 
was considerably lower than that of the patients with nonvalvular atrial 
fibrillation and a low flow profile; yet only two of the former patients 
(17%) had a history of embolic events. Sixteen (53%) of the 30 control 
patients in sinus rhythm with a high left atrial appendage velucrty also 
bad ia history of embulic evenh. 
In contrast, in our recent study (2) in a heterogeneous group of 140 
patients with nonvalvular and valvular atrial fibrillation. no clear 
relation was demonstrated between a history of systemic embulic 
events (ischemic strukc, transient cerebral ischemic attacks or pcriph- 
era1 embolism) and any of the five left atrial appendage blood velocity 
patterns observed. To determine whether differences in patient groups, 
definition of outcome: events or classification of left atrial appendage 
blood velocity patterns contributed to the different results of these 
studies, we have reanalyzed our data according to the methuds 
described by Miigge et a!. From the 140 paiicnts, a subgroup (;f 85 
patients with nunva\vu8ar atria! t?briPlatiran. a[( of whom wc~c in atriai 
fibrillation at the time of study, were identified (chronic atrial fibrilla_ 
h in 54 p:ttients, pasu.Xysmal atria! fibni&tian in 21, first cpisudc 
atria! fibrillation in 9j. No statistically significant dillcrcnccs were 
fOMld ill IhC pKV&tlCe of previous stroke or pefi@er$ e&&m 
b~Rvtx.m those patients With lefi arriai appendage bPooJ V&C@ 
<25 cm/s and those with velocity >25 cm/s (13 [3O%] of 44 VS. 7 [$7%] 
uf 41). IflOreOVer, the mean velocity in the 20 patients with embulic 
events (24 2 I3 cm/s, range 8 to 59) was nut significantly d&rent from 
that in the 65 patients without events (29 + 15 cm/s, range 7 to 69). 
~edlOrSt et al. (3) have also examined left atrial appendage blood 
velocity and embolic events in 54 patiems with nonvalvular atrial 
fibrillation, 23 (43%) of whom had paroxysmal atrial fibrillatioli alld 
were in sinus rhythm at the time of study. 111 that study, statjstjcally 
significant diflcrenccs were found in the mean left atrial appendage 
VClOCiiy btttWlCl1 10 piltik!~IS with ih hiStOly Ui’ ischcmic StrOl;e (25 2 
ItI Cm/s) aad 38 paticrils without stroke (39 2 33 cm/s, p < 0.115). When 
WC ~GUI$UC~ our data tu include 24 paticuts with paroxysmal atrial 
librillatiun studied in sinus rhythm, we found Ulai the mean left atrial 
appcndago v&city in 26 patients with embolic events (32 & 23 cm/s) 
W;PS IlOt significmrly dill’crcnt from that in X3 pit(iCllh wiihouc evcnl:, 
(3s 2 21 an/s). 
The inability to demonstrate a velocity-dependent increase in 
embulic events in a larger patient cohort, using the same methods as 
those used by other investigators, raises the possibility that the results 
reported by Miigge et al. (I) and Vcrborst et al. (3) may reflect chance 
findings in relatively small patient groups. Bt may also reflect the many 
confounding variables in retrospective analyses of this nature, HI is 
ditlicult to control fur treatment effects, fur example. Whereas antico- 
agulant therapy may have prevented strukcs in some patients, othrn 
may have commenced receiving anticoagulant therapy after an embulic 
event. iln addition, although ischemic strokes in patients with atrial 
fibrillation are presumed cardiucmbolic in origin, it is possible that 
carotid or ccrchrov;~sCular a1llCrosclcrosis may b12 lhr primary much- 
nnism responsible in a considerable proportion of cases. Finally, 
although our study and that of Miiggc ct al. arc in agrccmcnt that IOW 
left atrial appendage bluud v&city promotes spontaneous echo 
contrast and thrombus furmaGun, it is possible that intermediate or 
higher blood velocities or variable hemudynamic conditions may favor 
embulization (2). 
The relation between left atrial appendage blood velocity. sponta- 
neous echo contrast and thrumbus ftirmatiun is important because the 
finding of low velocities in patients with atrial fibrillation may influence 
the decision to commence anticoagulant therapy. However, proof of 
the therapeutic eficacy of such treatment slratification would require 
controlled, randomized, prospective evaluation. Given the existing 
data on anticoagulant therapy in patients with atrial fibrillation (4-7), 
jt is unlikely, on ethical grounds, that such studies will he conducted. 
DIANE FATKIN, MB, BS, l3Sr(M~u), FRACP 
RAYMOND KELLY, MD. FRACP. FACC 
MlCHAEL P. FENELEY. MD. FRACP, FACC 
Curdiolqy Depilt7mwf 
8. Vinrml ‘, Hrspifd 
